ZMapp Reinforces the Airway Mucosal Barrier Against Ebola Virus

Area of Science:

• Virology
• Immunology
• Biophysics

Background:

• Filoviruses, including Ebola virus, pose a significant threat due to potential transmission via respiratory droplets to mucosal surfaces.
• Understanding virus-host interactions at the airway mucus barrier is crucial for developing effective countermeasures against emerging infectious diseases.

Purpose of the Study:

• To investigate the penetration of Ebola virus pseudoparticles through human airway mucus.
• To evaluate the efficacy of ZMapp, an antibody cocktail, in inhibiting Ebola pseudovirus mobility within airway mucus.
• To assess the potential of topical antibody delivery as a strategy against airborne viral threats.

Main Methods:

• Preparation of Ebola pseudovirus (Zaire strain glycoproteins).
• High-resolution multiple-particle tracking of pseudoviruses in fresh human airway mucus.
• In vivo assessment of topical ZMapp delivery in a mouse model.

Main Results:

• Ebola pseudovirus demonstrated significant penetration capability within human airway mucus.
• ZMapp treatment substantially reduced the mobility of Ebola pseudovirus in mucus.
• Topical administration of ZMapp to mouse airways led to rapid clearance of Ebola pseudovirus.

Conclusions:

• Antibodies can effectively immobilize Ebola virions within the airway mucus barrier, limiting their access to epithelial cells.
• Topical delivery of pathogen-specific antibodies to the lungs presents a promising prophylactic and therapeutic strategy against emerging viral pathogens and biowarfare agents.